Merger and Acquisition Partnering Yearbook 2013

Date: January 1, 2013
Pages: 200
Price:
US$ 1,495.00
License [?]:
Publisher: CurrentPartnering
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), CD-ROM Mail Delivery, E-mail Delivery (Word)
ID: M4265CF30E8EN
Leaflet:

Download PDF Leaflet

Merger and Acquisition Partnering Yearbook 2013
SUMMARY

Provides comprehensive understanding and unprecedented access to the merger and acquisition deals and agreements entered into by the worlds leading healthcare companies during 2012

DESCRIPTION

The Merger and Acquisition Yearbook 2013 report series provides comprehensive understanding and unprecedented access to the M&A deals and agreements entered into by the worlds leading healthcare companies during 2012.

Using these reports, dealmakers will effectively and efficiently gain insight into the M&A activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.

The initial chapters of this report provide an orientation of 2012’s M&A dealmaking and business activities.

Chapter 1 provides an overview of the trends in M&A dealmaking during 2012.

Chapter 2 provides a review of the leading M&A deals during 2012. Deals are listed by headline value, signed by bigpharma and bigbiotech, and most active biopharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 3 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of 2012 M&A deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 4 provides a comprehensive directory of all M&A deals announced during 2012.The chapter is organized by company A-Z. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report series also includes numerous tables and figures that illustrate the trends and activities in bigpharma M&A dealmaking during 2012.

In conclusion, this report provides everything a prospective M&A dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2012.

BENEFITS

KEY BENEFITS

Merger and Acquisition Yearbook 2013 series provides the reader with the following key benefits:
  • In-depth understanding of recent M&A dealmaking trends during 2012
  • Comprehensive access to all M&A deals entered into by the world’s biopharma companies during 2012
  • Detailed access to actual M&A deals and contracts entered into by the leading fifty bigpharma companies
  • Understand the key M&A deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies
REPORT SCOPE

Merger and Acquisition Yearbook 2013 series is intended to provide the reader with an in-depth understanding and access to M&A trends and structure of deals entered into by leading companies worldwide.

Merger and Acquisition Yearbook 2013 includes:
  • Trends in dealmaking in the biopharma industry during 2012
  • Comprehensive directory of M&A deals in 2012
  • Links to online access to all deals and alliances
  • The leading M&A deals by value in 2012
  • Most active M&A dealmakers during 2012
In Merger and Acquisition Yearbook 2012 series the partnering and M&A deals are listed by:
  • Company A-Z
  • Headline value
Each deal title links via Weblink to an online version of the deal record at Current Agreements and where available, the contract document, providing easy access to each contract document on demand.
EXECUTIVE SUMMARY

CHAPTER 1 – TRENDS IN M&A DEALMAKING DURING 2012

1.1. Bigpharma dealmaking activity

CHAPTER 2 – LEADING M&A DEALS DURING 2012

2.1. Introduction
2.2. Top deals by value during 2012

CHAPTER 3 – BIGPHARMA M&A DEALS DURING 2012

3.1. Introduction
3.2. How to use bigpharma M&A deals
3.3. Bigpharma M&A company profiles for 2012
  Abbott
  Actavis
  Actelion
  Allergan
  Amgen
  Aspen Pharmacare
  Astellas
  AstraZeneca
  Baxter International
  Bayer
  Biogen Idec
  Boehringer Ingelheim
  Bristol-Myers Squibb
  Celgene
  CSL
  Daiichi Sankyo
  Dainippon Sumitomo
  Eisai
  Eli Lilly
  Endo Pharmaceuticals
  Forest Laboratories
  Galderma
  Gilead Sciences
  GlaxoSmithKline
  Grifols
  Hospira
  Johnson & Johnson
  Kyowa Hakko Kirin
  Lundbeck
  Menarini
  Merck & Co
  Merck KGaA
  Mitsubishi Tanabe
  Novartis
  Novo Nordisk
  Otsuka
  Pfizer
  Purdue
  Roche
  Sanofi
  Servier
  Shionogi
  Shire
  Takeda
  Teva
  Valeant
  Warner Chilcott
  Watson

CHAPTER 4 – M&A DEALS DIRECTORY 2012

4.1. Introduction
4.2. Company A-Z

ABOUT WILDWOOD VENTURES

Current Partnering
Current Agreements
Current Reports
Recent titles from CurrentPartnering
Order Form – Reports

TABLE OF FIGURES

Figure 1: Bigpharma – top 50 – January to December 2012
Figure 2: Bigpharma deal frequency – 2012
Academic/Non-Profit Partnering Yearbook 2013 US$ 1,495.00 Jan, 2013 · 200 pages
Animal Health Partnering Yearbook 2013 US$ 1,495.00 Jan, 2013 · 200 pages
Antibody Partnering Yearbook 2013 US$ 1,495.00 Jan, 2013 · 200 pages
Bigbiotech Partnering Yearbook 2013 US$ 1,495.00 Jan, 2013 · 200 pages
Bigpharma Partnering Yearbook 2013 US$ 1,495.00 Jan, 2013 · 200 pages

Ask Your Question

Merger and Acquisition Partnering Yearbook 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: